The era of multi-agency caution around living matter patents is over
After a quarter century of shared oversight, Argentina has quietly returned sole authority over biotechnology patent criteria to its national patent office, dissolving a multi-agency framework built in 2001 to govern how living matter could be protected as intellectual property. The move, joined by the agriculture and industry ministries, signals a deliberate pivot toward streamlining innovation protections in a sector long shaped by cautious institutional consensus. With a second, more consequential deregulation imminent—one that would lift explicit restrictions on patenting genetically modified organisms—Argentina is repositioning itself within a global conversation about who owns the building blocks of life, and under what terms.
- A regulatory architecture that required multiple state agencies to agree before patent rules could change has been dismantled overnight, ending 25 years of institutional caution in a single joint resolution.
- The biotech and seed industries, long frustrated by restrictions that left genetic innovations outside the reach of patent protection, are treating the move as a turning point rather than a technicality.
- A second deregulation—the repeal of Resolution 283/15—is days away and would remove explicit prohibitions on patenting genetically modified plants, animals, and seeds, sending the rules back to the broader 1996 Patent Law.
- Legal experts warn that without the guardrails built in 2001, the boundary between invention patents and plant breeder rights could blur, potentially extending IP coverage over genetic material in ways the original framework was designed to prevent.
- The outcome now rests with INPI: the agency holds newly expanded authority to reinterpret decades of accumulated restrictions, and whether it moves boldly or cautiously will define the shape of Argentine biotech IP for years to come.
Argentina took a quiet but consequential step this week when officials from the agriculture and industry ministries jointly revoked a pair of 2001 resolutions that had required multi-agency consensus before the country's patent office could update its criteria for protecting living organisms. For 25 years, any adjustment to how INPI evaluated biotech patent applications first required sign-off from the agriculture ministry and a standing working group of representatives from several state bodies. The government's rationale for dismantling this structure is direct: it created bureaucratic friction where technical expertise should have been sufficient.
This first move is only the opening act. Officials confirmed that within days, INPI will repeal Resolution 283/15, a regulation that explicitly excludes plants, animals, seeds, and genetically modified organisms from patent eligibility. Once that rule falls, biotech applications will be governed directly by Argentina's 1996 Patent Law—without the additional restrictions that have accumulated over two decades. The private sector is reading both moves as a green light, describing them as a step toward aligning Argentina with international standards for protecting genetic innovations.
What the changes do not immediately alter is also worth noting. Argentina's Patent Law still holds that plants and animals themselves cannot be patented, and plant varieties remain protected through a separate system of breeder rights. The deregulation opens a door to reconsidering how strictly those boundaries are drawn—not to erasing them outright.
Alfredo Paseyro of the Argentine Seed Breeders Association called the derogation a necessary precursor to a broader review of biotech patent evaluation. Legal expert María Laura Villamayor, who helped design the original 2001 framework, offered a cautionary note: that system was built precisely to prevent overlap between patent protection and plant breeder rights, and without its guardrails, an expansive interpretation of patentability could extend coverage to genetic material that traditionally belonged in a different regime.
What happens next depends on how INPI chooses to use its newly restored authority. The agency now has the legal space to revisit years of restrictive criteria. Whether it moves to fundamentally broaden what can be patented or adjusts only at the margins remains an open question—but the government's direction is unmistakable.
Argentina's government took a quiet but significant step this week to reshape how the country protects agricultural biotechnology. On Thursday, officials from the agriculture and industry ministries jointly revoked a pair of resolutions from 2001 that had required multiple state agencies to sign off whenever the country's patent office wanted to update its rules for protecting living organisms and natural substances. The move eliminates what the government describes as bureaucratic friction—an extra layer of administrative validation that slowed the process of keeping patent criteria in line with scientific and legal advances.
For a quarter century, the system had worked like this: whenever Argentina's National Institute of Industrial Property, known as INPI, wanted to adjust how it evaluated patent applications for biotech innovations, it first needed approval from the agriculture ministry. A permanent working group made up of representatives from INPI, the seed institute, the agricultural health authority, and other state bodies had to reach consensus on any changes. The government's reasoning for dismantling this structure is straightforward—it created rigidity and complexity where technical expertise should have been enough. By returning full authority to INPI to define and update its own examination guidelines, officials argue, the country can respond more nimbly to developments in science and international practice.
But this first move is only the opening. Officials confirmed that within days, INPI will repeal another regulation—Resolution 283/15—that currently imposes specific restrictions on what can be patented when it comes to living matter. That resolution explicitly excludes plants, animals, seeds, and other biological components capable of producing a complete organism, even if genetically modified. Once that rule falls away, biotech patent applications will be governed directly by Argentina's 1996 Patent Law, without the additional limitations that have accumulated over the past two decades.
The private sector is reading these moves as a green light. Industry sources describe the changes as a "very good signal" for innovation and a step toward aligning Argentina with more favorable international standards for protecting biotech developments. The elimination of the multi-agency approval requirement reduces uncertainty and gives INPI clearer ground to make decisions based on technical criteria and existing law. For companies developing genetic events, seed improvements, and other innovations applied to agriculture, the potential impact is substantial. If INPI does indeed revisit criteria that have restricted protection for certain technologies, the landscape for intellectual property in biotech could shift meaningfully.
It's important to note what these changes do not immediately alter. Argentina's Patent Law still states that plants and animals themselves cannot be patented. Plant varieties remain protected through a separate system of plant breeder rights rather than patents. The changes do not modify that foundational structure. What they do is open the door to a reconsideration of how strictly those boundaries are drawn and what kinds of technological innovations embedded in seeds or organisms might qualify for patent protection under the existing law.
Alfredo Paseyro, executive director of the Argentine Seed Breeders Association, framed the derogation as a necessary precursor to a broader review of how biotechnology patents are evaluated. He noted that since 2001, various consultative mechanisms and restrictive rules had gradually narrowed the scope of certain protections. "First you had to eliminate this joint resolution," he said. "This strengthens patents related to biotech events." María Laura Villamayor, a legal expert in plant breeder rights and intellectual property who participated in the original interdisciplinary group that created those 2001 rules, offered historical context. That group was assembled precisely to build consistent technical and legal criteria for protecting living matter across different intellectual property regimes. The goal was to prevent overlap—to make clear which innovations belonged in the patent system and which should be protected through plant breeder rights instead. Without those guardrails, she explained, an overly broad interpretation of patentability could have allowed characteristics incorporated into seeds to be protected as invention patents, potentially extending coverage to genetic material that traditionally fell under the plant variety protection system.
What happens next depends on how INPI interprets its newly expanded authority. The agency now has the technical and legal space to reconsider criteria that have restricted biotech patents for years. Whether it will use that space to fundamentally broaden what can be patented, or whether it will maintain most existing boundaries while adjusting at the margins, remains to be seen. The biotech industry is clearly hoping for the former. The government's signal is clear: the era of multi-agency caution around living matter patents is over.
Citas Notables
This strengthens patents related to biotech events— Alfredo Paseyro, executive director of the Argentine Seed Breeders Association
The introduction of an additional administrative validation instance, outside the competent technical body, made the process of defining and updating patentability criteria more complex and bureaucratic— Government reasoning in the joint resolution
La Conversación del Hearth Otra perspectiva de la historia
Why did Argentina need to eliminate this 25-year-old rule now? What changed?
The government's argument is that the old system created unnecessary bureaucratic friction. Having multiple agencies sign off on every update to patent criteria meant the rules couldn't keep pace with scientific advances or international practice. It was a brake on the system.
But that system was put in place for a reason, wasn't it? Someone designed it that way deliberately.
Absolutely. In 2001, there were genuine technical and legal questions about how to protect biotech innovations without creating overlap between patent law and plant breeder rights. The multi-agency group was meant to prevent confusion—to keep patents from accidentally swallowing protections that belonged in other systems.
So what's different now? Are those concerns gone?
Not entirely. But the government is betting that INPI, as the technical patent authority, is capable of managing those boundaries on its own. And there's also a sense that Argentina has fallen behind international standards—that other countries have found ways to protect biotech innovations more generously while still maintaining legal clarity.
What does "more generously" actually mean in practice? What gets patented that couldn't before?
That's the open question. The rules that are about to be repealed explicitly exclude genetically modified plants, animals, and seeds from patent protection. Once those restrictions fall away, INPI could theoretically allow patents on things like specific genetic events or modifications—innovations that are currently only protectable through plant breeder rights.
And the seed companies want that badly?
Very much. They see it as a way to get stronger, longer-lasting protection for their innovations. Plant breeder rights are narrower and shorter-lived than patents. If you can patent a genetic innovation instead, you have more control and more time.
Does this mean Argentina is about to become a free-for-all for biotech patents?
Not necessarily. The Patent Law itself still says plants and animals can't be patented. What's changing is the administrative criteria that interpret that law. INPI will have more flexibility to decide what counts as a patentable innovation versus what counts as a plant or animal. It's a shift in interpretation, not a wholesale legal change—but interpretation matters enormously.